Results 31 to 40 of about 68,732 (285)
The Promising Viral Threat to Bacterial Resistance: The Uncertain Patentability of Phage Therapeutics and the Necessity of Alternative Incentives [PDF]
, 2014 Bacteriophages, or “phages,” are a category of highly adept and adaptable viruses that can infect and kill bacteria. With concerns over the burgeoning antibiotic-resistance crisis looming in recent years, scientists and policymakers have expressed a ...
Todd, Kelly
core +2 more sources
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders [PDF]
Orphanet Journal of Rare Diseases, 2011 Orphan drugs are often approved under exceptional circumstances, requiring submission of additional data on safety and effectiveness through registries. These registries are mainly focused on one drug only and data is frequently incomplete. Some registries also address phenotypic heterogeneity and natural history data and publications on these aspects ...
Hollak, C.E.M. +3 more
openaire +7 more sources
PharmacoEconomics - Open, 2022 The National Institute for Health and Care Excellence (NICE) is responsible for ensuring that patients in England and Wales can access clinically and cost-effective treatments. However, NICE's processes pose significant reimbursement challenges for treatments for rare diseases.
Dawn Lee +5 more
openaire +3 more sources
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Hepatology, EarlyView., 2022 Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu +11 more
wiley +1 more source
An expanding range of targets for kynurenine metabolites of tryptophan [PDF]
, 2013 The kynurenine pathway of tryptophan metabolism accounts for most of the tryptophan that is not committed to protein synthesis and includes compounds active in the nervous and immune systems.
Darlington, L. Gail +2 more
core +1 more source
Biomedicines, 2021 Following myocardial infarction, reperfusion injury (RI) is commonly observed due to the excessive formation of, e.g., reactive oxygen species (ROS).
Per-Christian Berg +4 more
doaj +1 more source
Microbial Cell Factories, 2022 Background The anthraquinone-fused 10-membered enediynes (AFEs), represented by tiancimycins (TNMs), possess a unique structural feature and promising potentials as payloads of antitumor antibody–drug conjugates.
Manxiang Zhu +5 more
doaj +1 more source
Access to Life-Saving Medicines and Intellectual Property Rights: An Ethical Assessment [PDF]
, 2011 © 2011 Cambridge University Press. Online edition of the journal is available at http://journals.cambridge.org/action/displayJournal?jid=CQHDying before one’s time has been a prominent theme in classic literature and poetry.
Aquinas +20 more
core +2 more sources
Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84 [PDF]
, 2017 Medium chain fatty acids can activate the pro-inflammatory receptor GPR84 but so also can molecules related to 3,3′-diindolylmethane. 3,3′-Diindolylmethane and decanoic acid acted as strong positive allosteric modulators of the function of each other and
De Vos, Steve +8 more
core +3 more sources
Orphan drugs: Unmet societal need for non-profitable privately supplied new products
Research Policy, 2007 Due to the severity of rare diseases, the societal need for biopharmaceutical treatments for these diseases is high, despite low numbers of patients. Therefore, we investigated the barriers currently hindering the willingness to develop orphan drugs in the Netherlands.
Moors, E.H.M., Faber, J.
openaire +3 more sources